Cumulative incidence of PSA progression was 342 % ( 286-399 ) in the STAS group , 396 % ( 336-455 ) in the STAS plus zoledronic acid group , 292 % ( 238-348 ) in the ITAS group , and 260 % ( 208-314 ) in the ITAS plus zoledronic acid group .